Health Economics›Gastric cancer›Adjuvant therapy

Adjuvant therapy

Gastric cancer · 18 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin and Docetaxel (DCb) Variant #06	—	R 5 501	21d	—	55.3 mo	6	R 33 004 PFS proxy	—
Doxifluridine and Mitomycin Variant #01 Partial	—	R 4 539	90d	—	—	~1	~R 4 539 indirect	—
FP/Capecitabine and RT Variant #01	—	R 3 392	63d	—	—	~4	~R 7 142 indirect	—
FAM Variant #01	—	R 2 760	56d	—	—	~2	~R 5 520 indirect	—
CapeOx Variant #01	—	R 2 620	21d	—	—	12	R 31 438 PFS proxy	1
Docetaxel and S-1 Variant #01 Partial	—	R 2 597	21d	—	—	8	R 20 775 PFS proxy	1
FULV and RT Variant #04	—	R 1 551	14d	—	36.0 mo	5	R 7 754 PFS proxy	1
Capecitabine and Cisplatin (CX) Variant #01	—	R 1 480	21d	~5.4 mo	~11.1 mo	~6	~R 8 879 PFS proxy · indirect	9
Fluorouracil and Mitomycin Variant #01	—	R 1 432	42d	—	—	~35	~R 50 131 indirect	—
SOX Variant #01 Partial	—	R 1 265	21d	~5.6 mo	—	~2	~R 2 530 PFS proxy · indirect	2
FULV Variant #29	—	R 806	14d	—	~7.5 mo	~5	~R 4 028 PFS proxy · indirect	1
FA Variant #01	—	R 693	21d	—	—	~2	~R 1 387 indirect	—
Fluorouracil monotherapy Variant #01	—	R 647	28d	—	~10.8 mo	~2	~R 1 294 PFS proxy · indirect	2
Cisplatin and S-1 Variant #01 Partial	—	R 441	28d	~5.5 mo	~14.1 mo	~8	~R 3 530 PFS proxy · indirect	10
FULV/FULV and RT Partial	—	—	—	—	—	—	—	—
UFT monotherapy Variant #04 Partial	—	—	28d	—	—	52	—	1
Observation Partial	—	—	—	—	35.9 mo	—	—	7
S-1 monotherapy Variant #01 Partial	—	—	21d	—	—	2	—	2

18 of 18 regimens shown